MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)

3 Months Ended

Mar. 31, 2022

Novartis Institutes for BioMedical Research, Inc.

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement were as follows (in thousands):

	Three Months Ended March 31,
	2022		2021
Revenue related to Novartis agreement:
Recognition of upfront license fee	$	7,018	$	6,200
Research services	1,877		1,661
Total	$	8,895	$	7,861

Biogen MA, Inc.

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement were as follows (in thousands):

	Three Months Ended March 31,
	2022		2021
Revenue related to Biogen agreement:
Recognition of license and stand-ready fee	$	7,306	$	7,306
Research services	3,887		3,145
Total	$	11,193	$	10,451

Kite Pharma, Inc.

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement were as follows (in thousands):

	Three Months Ended March 31,
	2022		2021
Revenue related to Kite agreement:
Recognition of license and stand-ready fee	$	6,159	$	6,159
Research services	149		129
Total	$	6,308	$	6,288

Sanofi S.A.

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement were as follows (in thousands):

	Three Months Ended March 31,
	2022		2021
Revenue related to Sanofi agreement:
Recognition of upfront fee	$	311	$	227
Research services	978		679
Milestone achievement	210		154
Total	$	1,499	$	1,060